“South Africa has officially rolled out lenacapavir, a revolutionary long-acting HIV prevention injection administered twice yearly, marking a historic milestone in the country’s fight against HIV. The initiative, praised by the World Health Organization (WHO), positions South Africa as a global leader in adopting innovative prevention technologies to reduce new infections and move closer to ending HIV.”
South Africa has taken a bold step in its decades-long battle against HIV by launching the national rollout of lenacapavir, a groundbreaking long-acting injectable designed to prevent HIV infection. The announcement, made in Secunda, Mpumalanga province, was hailed as a “historic turning point” by President Cyril Ramaphosa, who emphasized the drug’s potential to transform the country’s healthcare landscape and save countless lives.
Lenacapavir represents a major scientific breakthrough in HIV prevention. Unlike traditional oral pre-exposure prophylaxis (PrEP) medications that require daily adherence, lenacapavir is administered only twice a year. This innovation dramatically reduces the burden of daily pill-taking, a challenge that has long hindered consistent use of HIV prevention therapies. By simplifying adherence, the injection offers powerful protection against HIV infection and could significantly reduce new cases in high-burden communities.
The World Health Organization (WHO) commended South Africa’s leadership in adopting lenacapavir, noting that the country is among the first globally to move from policy to implementation. WHO Director-General Dr. Tedros Adhanom Ghebreyesus praised the government’s swift action in updating its essential medicines list, securing early supplies, and preparing health systems for rollout. “It demonstrates what is possible when governments, communities, and partners work together with clear purpose,” he said, calling the initiative a milestone in the global fight against HIV.
The rollout is ambitious in scale. According to President Ramaphosa, 360 public health facilities across six provinces and 24 high-burden districts are already prepared to administer the injection. The government has set a target of reaching one million people by the end of 2027, with a broader goal of three million citizens over the next three years. This expansion reflects South Africa’s determination to ensure that lifesaving medicines are accessible to all, not just the wealthy.
Funding for the rollout has been secured through a partnership between the South African government, the Global Fund, and the Children’s Investment Fund Foundation (CIFF). Together, these stakeholders have committed R1.3 billion to support the program. Ramaphosa emphasized that the initiative aligns with the African Union’s broader goal of producing 60% of the continent’s health products locally by 2040, underscoring South Africa’s commitment to affordable generic medicines, technology transfer, and local manufacturing.
The significance of lenacapavir extends beyond its medical benefits. For many South Africans, the injection symbolizes hope and resilience in the face of a devastating epidemic. Ramaphosa described the drug as “the triumph of science over despair” and “the power of innovation to save lives.” His remarks highlight the broader social and emotional impact of the rollout, which offers families and communities renewed optimism for a future free from HIV.
South Africa has long been recognized as a global leader in HIV response, driven by strong political commitment, scientific excellence, and community partnerships. The introduction of lenacapavir builds on decades of progress, including the widespread availability of antiretroviral treatment (ART) and the expansion of prevention programs. By integrating this new technology into public health strategies, the country is reinforcing its role as a pioneer in combating HIV and reducing health inequities.
Experts believe that lenacapavir could be a game-changer in regions with high HIV prevalence. The twice-yearly injection is particularly suited to populations that struggle with daily medication adherence, such as young people and marginalized communities. By lowering barriers to prevention, lenacapavir has the potential to dramatically reduce infection rates and accelerate progress toward ending HIV by 2030.
The rollout also reflects a broader shift in global health policy toward innovative, people-centered solutions. WHO officials have pledged continued support for South Africa’s efforts, emphasizing the importance of ensuring that new prevention technologies reach those who need them most. As Dr. Tereza Kasaeva, Director of WHO’s Department for HIV, TB, Hepatitis and STIs, noted, “South Africa’s rollout of lenacapavir demonstrates the country’s continued commitment to expanding access to innovative HIV prevention tools.”
In conclusion, the launch of lenacapavir in South Africa marks a pivotal moment in the fight against HIV. By embracing this revolutionary injection, the country is not only protecting millions of lives but also setting a powerful example for the rest of the world. The initiative embodies the triumph of science, the strength of community, and the unwavering determination to end HIV once and for all.
